City
Epaper

SEBI needs to act rationally in insider trading verdicts: Kiran Mazumdar-Shaw

By IANS | Updated: July 9, 2021 21:40 IST

Mumbai, July 9 A day after the capital market regulator barred brokerage firm Allegro Capital Pvt Ltd and ...

Open in App

Mumbai, July 9 A day after the capital market regulator barred brokerage firm Allegro Capital Pvt Ltd and its Chairman from the securities market for one year over insider trading in the shares of Biocon Ltd, the biopharmaceutical major's Executive Chairperson, Kiran Mazumdar-Shaw on Friday said that SEBI should act "rationally" in terms of judgement in matters of alleged insider trading.

She questioned the basis for relating the Mazumdar Shaw Medical Foundation to Biocon in the judgement.

"SEBI bars Allegro Capital, its CEO over insider trading in Biocon shares - Crazy logic. What does MSMF have to do with Biocon? The officer concerned needs to explain her convoluted hypothesis. SEBI needs to act rationally in insider trading judgements," Shaw said in a tweet.

The SEBI, in its order on Thursday, had said that Allegro Capital Chairman and CEO Kunal Ashok Kashyap, by virtue of his directorship in Mazumdar Shaw Medical Foundation and his majority shareholding in the trading member Allegro Capital which was used by the officers of the company, was allegedly in a position where he was in regular touch with the officers of the company.

A SEBI order said that in 2018, Biocon had made an announcement of an "exclusive global collaboration" with Sandoz on "NextGeneration Biosimilars" and the capital market regulator observed that after the public announcement was made, the scrip witnessed rise of 5.6 per cent in the closing price on the next day post the announcement.

It initiated an investigation to ascertain whether certain persons or entities have traded in the scrip of Biocon while they were in possession of unpublished price sensitive information and were, thus, in violation of norms to prohibit insider norms.

As per the allegations, Allegro Capital was in a temporary business relationship with Biocon and consequent to the same, Kashyap was in frequent communication with the officers of the company.

The SEBI probe found that the noticees have made wrongful notional gains of over Rs 24.68 lakh, and has directed both the brokerage and its Chairman and CEO Kashyap to jointly disgorge the amount.

The market regulator has also imposed a penalty of Rs 10 lakh each on the investment advisory firm and its head.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Allegro capital pvt ltdBiocon ltdKunal ashok kashyap
Open in App

Related Stories

BusinessPLI scheme for pharmaceuticals: Govt releases Rs 166-cr incentives in first batch

HealthBiocon Q3FY23 revenue at Rs 3,020 crore, up 36%

EntertainmentBengaluru celebrates as Ricky Kej's brings home his third Grammy

HealthKiran Mazumdar-Shaw unveils Siddhartha Mukherjee's latest book 'The Song of The Cell' in B'luru

BusinessKiran Mazumdar Shaw leads investment in Gytree.com - women's health platform founded by Shaili Chopra

International Realted Stories

InternationalTaiwan detects 7 sorties of Chinese aircraft near its territory

InternationalTaiwan: MAC flags essay contest tied to CCP-affiliated publisher for possible legal breach

InternationalArab Parliament, AL condemn Israeli airstrikes near Syria's Presidential Palace

InternationalSecond Emirati-Iraqi Business Forum discusses enhancing trade partnerships

InternationalEuropean Commission welcomes Ukraine-US fossil fuel deal that doesn't hinder EU accession